Results 131 to 140 of about 32,249 (192)

Skin exposure to soil microbiota elicits changes in cell-mediated immunity to pneumococcal vaccine. [PDF]

Sci Rep
Roslund MI, Nurminen N, Oikarinen S, Puhakka R, Grönroos M, Puustinen L, Kummola L, Parajuli A, Cinek O, Laitinen OH, Hyöty H, Sinkkonen A.   +11 more
europepmc   +1 more source

<i>Streptococcus pneumoniae</i> serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? [PDF]

Hum Vaccin Immunother
Dhawale P, Shah S, Sharma K, Sikriwal D, Kumar V, Bhagawati A, Dhar S, Shetty P, Ahmed S.   +8 more
europepmc   +1 more source

Implementation of a Targeted Technologic Screening Tool to Increase Pneumococcal Vaccine Uptake in Health-System Retail Pharmacies: A Quality Improvement Initiative. [PDF]

Innov Pharm
Skogg A, Zagel AL, May O'Donnell R, Philbrick AM, Nelson MR, Schlichte A, Klasen KA.   +6 more
europepmc   +1 more source

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10). [PDF]

Vaccines (Basel)
Jotterand V, Jagannath V, Diaz AA, Velez JD, Letica A, Perez SN, Clark R, Caraco Y, Degen O, Park KH, Ünal S, Wittke F, Hurtado K, Churchill C, Zhang Y, Fernsler D, Li J, Buchwald UK, Platt H.   +18 more
europepmc   +1 more source

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6). [PDF]

Clin Infect Dis
Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL, STRIDE-6 Study Group.   +13 more
europepmc   +1 more source

Factors Associated with Influenza and Pneumococcal Vaccine Hesitancy Among Patients with AECOPD using the 3C Model: A Cross-Sectional Study in China

Xin Y, He R, Ren X, Yang T, Wang Y, Su X.   +5 more
europepmc   +1 more source